风湿病患者破伤风/白喉疫苗接种的安全性与免疫原性:前瞻性多中心队列研究
该研究在瑞士纳入284例风湿病患者(RA 131例、SpA/PsA 114例、血管炎39例)和253名健康对照,评估破伤风/白喉疫苗加强接种的安全性与免疫原性。接种后3个月,破伤风保护率健康对照100%、患者98%,白喉保护率分别为84%和73%;利妥昔单抗仅负向影响破伤风免疫原性,MTX仅负向影响白喉抗体应答,未记录疫苗相关严重不良事件。
要点
- 破伤风/白喉加强疫苗在风湿病患者中安全,未记录疫苗相关严重不良事件。
- 破伤风疫苗免疫原性良好,白喉成分免疫原性较低。
- 利妥昔单抗钝化破伤风应答,MTX钝化白喉抗体应答。
核心结论
- 破伤风/白喉加强疫苗接种安全,破伤风疫苗有免疫原性而白喉成分免疫原性较低。
- 利妥昔单抗和MTX分别钝化破伤风和白喉的疫苗应答。
研究设计与样本
- 患者包括RA 131例、中轴型SpA/PsA 114例、血管炎39例,89%使用免疫抑制/免疫调节药物。
- 接种前及接种后1个月、3个月采血,ELISA检测疫苗抗原抗体,采用混合模型多变量分析,缺失数据多重插补。
主要发现
- 接种后3个月,破伤风保护率健康对照100%、患者98%;白喉保护率健康对照84%、患者73%。
- 健康对照和SpA/PsA患者的疫苗应答显著高于RA和血管炎患者。
- 多变量模型中,利妥昔单抗是唯一负向影响破伤风免疫原性的因素,仅MTX治疗负向影响白喉抗体应答。
- 未记录疫苗相关严重不良事件。
临床怎么用
- 风湿病患者可安全接种破伤风/白喉加强疫苗,但使用利妥昔单抗或MTX者疫苗应答可能减弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to assess the safety and immunogenicity of a diphtheria/tetanus vaccine booster dose in three different patient groups with rheumatic diseases on a variety of immunosuppressive/immunomodulatory medications compared with healthy controls (HCs). METHODS: We conducted a multi-centre prospective cohort study in Switzerland. We enrolled patients with RA, axial SpA/PsA, vasculitis (Behçet's disease, ANCA-associated vasculitis) and HCs. Diphtheria/tetanus vaccination was administered according to the Swiss vaccination recommendations. Blood samples were drawn before vaccination, and 1 month and 3 months afterwards. Antibody concentrations against vaccine antigens were measured by ELISA. Immunogenicity was compared between patient and medication groups. A mixed model was applied for multivariate analysis. Missing data were dealt with using multiple imputation. RESULTS: Between January 2014 and December 2015, we enrolled 284 patients with rheumatic diseases (131 RA, 114 SpA/PsA, 39 vasculitis) and 253 HCs. Of the patients, 89% were on immunosuppressive/immunomodulatory medication. Three months post-vaccination 100% of HCs vs 98% of patients were protected against tetanus and 84% vs 73% against diphtheria. HCs and SpA/PsA patients had significantly higher responses than RA and vasculitis patients. Assessing underlying diseases and medications in a multivariate model, rituximab was the only factor negatively influencing tetanus immunogenicity, whereas only MTX treatment had a negative influence on diphtheria antibody responses. No vaccine-related serious adverse events were recorded. CONCLUSION: Diphtheria/tetanus booster vaccination was safe. Tetanus vaccination was immunogenic; the diphtheria component was less immunogenic. Vaccine responses were blunted by rituximab and MTX. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, Identifier: NCT01947465.
引用
- Bühler S, Jaeger VK, Adler S, et al. Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. Rheumatology (Oxford). 2019. PMID: 30877773. doi:10.1093/rheumatology/kez045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。